Kymera Therapeutics, Inc. (KYMR) Stock Price & Analysis

Kymera Therapeutics, Inc. (KYMR) rose 0.09% to USD 117.39 as of September 8, 2026 at 05:42 UTC, according to Nexqual real-time market data.

KYMR last closed at USD 117.28; the session ranged USD 112.77–118.28 on volume of 378,568 shares. Market capitalization is $9.66B, with a 52-week range of USD 42.71–130.05 (NGM). Source: Nexqual, September 8, 2026 at 05:42 UTC.

Key Statistics (as of September 8, 2026 at 05:42 UTC)

Technical Analysis (KYMR)

Nexqual's technical model rates KYMR "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:42 UTC.

Analyst Ratings (KYMR)

Wall Street analysts rate KYMR "Strong Buy" based on 21 analysts, with a mean price target of USD 134.71 (range USD 111–170), per Nexqual as of September 8, 2026 at 05:42 UTC.

Earnings (KYMR)

Recent Earnings History

Source: Nexqual, September 8, 2026 at 05:42 UTC.

Financials & Fundamentals (KYMR)

Source: Nexqual, September 8, 2026 at 05:42 UTC.

Financial Health Score (KYMR)

Nexqual rates Kymera Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 05:42 UTC.

Ownership (KYMR)

Source: Nexqual, September 8, 2026 at 05:42 UTC.

Leadership (KYMR)

Kymera Therapeutics, Inc. is led by Nello Mainolfi (age 46), Co-Founder, President, CEO & Director, per Nexqual as of September 8, 2026 at 05:42 UTC.

Major Backers & Investors (KYMR)

Notable institutional backers of Kymera Therapeutics, Inc. include FMR, LLC, T. Rowe Price, Baker Bros. Advisors, LP, according to Nexqual as of September 8, 2026 at 05:42 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, September 8, 2026 at 05:42 UTC.

From Kymera Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our success also depends on our ability to defend and enforce our intellectual property rights, preserve the confidentiality of our proprietary information, and operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and proprietary rights of third parties.
• Our approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner.
• We are focused on deploying our technology against diseases in areas of significant patient need that are not yet meaningfully addressed by traditional medicines, and where we believe TPD is the only or best way to elucidate the desired biology or clinical outcome.
• Our TPD approach is rooted in a deep understanding of the relationship between E3 ubiquitin ligases and target proteins, which allows us to identify the properties that make a target both ligandable and degradable and to determine how multiple factors impact potency, selectivity, pharmacokinetics (PK) and pharmacodynamics (PD).

Partnerships

• If Gilead exercises its option to exclusively license the program, Gilead will have global rights to develop, manufacture and commercialize all products resulting from the collaboration.   Collaboration Agreement with Sanofi (formerly Genzyme Corporation) On July 7, 2020, we entered into a collaboration agreement, or the Original Sanofi Agreement, with Genzyme Corporation, a subsidiary of Sanofi, to co-develop drug candidates directed to two biological targets.
• On November 15, 2022, we entered into an Amended and Restated Collaboration and License Agreement with Sanofi, or the Amended Sanofi Agreement, which amended the Original Sanofi Agreement to revise certain research terms and responsibilities set forth under the Original Sanofi Agreement.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:42 UTC. This page is informational and not investment advice.